Patient characteristics in cohort 1
| . | d-rsKIR . | dsKIR . | rsKIR . | nsKIR . | P . |
|---|---|---|---|---|---|
| n | 17 | 20 | 15 | 62 | |
| Sex of host, male, n (%) | 8 (47.1) | 11 (55) | 10 (66.7) | 40 (64.5) | NS |
| Age of host, median (range), y | 29 (18-53) | 42.5 (26-63) | 28 (15-43) | 31.5 (15-58) | .003 |
| Age of donor, median (range), y | 45 (14-64) | 27 (8-65) | 40 (13-54) | 29 (12-60) | NS |
| Donor and host sex group, n (%) | |||||
| Male-male | 8 (47.1) | 8 (40) | 10 (66.7) | 28 (45.2) | |
| Male-female | 8 (47.1) | 4 (20) | 3 (20) | 15 (24.2) | |
| Female-male | 0 (0) | 5 (25) | 0 (0) | 12 (19.4) | |
| Female-female | 1 (5.9) | 3 (15) | 2 (13.3) | 7 (11.3) | |
| Donor and host relationship, n (%) | |||||
| Child-parent | 4 (23.5) | 12 (60) | 3 (20) | 22 (35.5) | |
| Sibling | 3 (17.6) | 3 (15) | 5 (33.3) | 22 (35.5) | |
| Parent-child | 10 (58.8) | 5 (25) | 7 (46.7) | 18 (29) | |
| Disease category, n (%) | <.01 | ||||
| AML | 10 (58.8) | 7 (35) | 4 (26.7) | 37 (50.9) | |
| ALL | 2 (11.8) | 3 (15) | 8 (53.3) | 21 (33.9) | |
| CML | 2 (11.8) | 0 (0) | 1 (6.7) | 2 (3.2) | |
| MDS | 3 (17.6) | 10 (50) | 2 (13.3) | 2 (3.2) | |
| Disease risk, n (%) | |||||
| High | 6 (35.3) | 10 (50) | 4 (26.7) | 9 (14.5) | .011 |
| HCT-CI score, n (%) | NS | ||||
| 0 | 15 (88.2) | 18 (90) | 11 (73.3) | 56 (90.3) | |
| ≥1 | 2 (11.8) | 2 (10) | 4 (26.7) | 6 (9.7) | |
| MRD status before transplantation, n (%) | NS | ||||
| Negative | 10 (58.8) | 8 (40) | 6 (40) | 29 (46.8) | |
| FCM and molecular positive | 5 (29.4) | 8 (40) | 4 (26.7) | 11 (17.7) | |
| Only FCM positive | 1 (5.9) | 3 (15) | 2 (13.3) | 6 (9.7) | |
| Only molecular positive | 1 (5.9) | 1 (5.0) | 3 (20) | 16 (25.8) | |
| Loci of HLA-A,B,DR mismatch, n (%) | NS | ||||
| 1 | 1 (5.9) | 0 (0) | 0 (0) | 3 (4.8) | |
| 2 | 4 (23.5) | 1 (5.0) | 0 (0) | 10 (16.1) | |
| 3 | 12 (70.6) | 19 (95) | 15 (100) | 49 (79) | |
| Missing self (donor ligand view), n (%) | 0 (0) | 0 (0) | 15 (100) | 62 (100) | <.01 |
| Missing self (host ligand view), n (%) | 0 (0) | 20 (100) | 0 (0) | 62 (100) | <.01 |
| Ligand-ligand GVH mismatch, n (%) | 0 (0) | 20 (100) | 0 (0) | 11 (28.2) | <.01 |
| Donor KIR haplotype, n (%) | NS | ||||
| AA | 9 (52.9) | 9 (45) | 12 (80) | 33 (55) | |
| BX | 8 (47.1) | 11 (55) | 3 (20) | 27 (45) | |
| KIR2DL1 single+group, n (%) | <.01 | ||||
| nsKIR(donor C1C1 to host C1C1) | 0 (0) | 0 (0) | 0 (0) | 43 (69.4) | |
| d-rsKIR(donor C2Cx to host C2Cx) | 17 (100) | 6 (30) | 7 (46.7) | 9 (14.5) | |
| dsKIR(donor C2CX to host C1C1) | 0 (0) | 14 (70) | 0 (0) | 9 (14.5) | |
| rsKIR(donor C1C1 to host C2Cx) | 0 (0) | 0 (0) | 8 (53.3) | 1 (1.6) | |
| KIR2DL2/L3 single+group, n (%) | <.01 | ||||
| nsKIR (donor C2C2 to host C2C2) | 0 (0) | 0 (0) | 0 (0) | 1 (1.6) | |
| d-rsKIR (donor C1Cx to host C1Cx) | 17 (100) | 16 (80) | 9 (60) | 54 (88.5) | |
| dsKIR(donor C1CX to host C2C2) | 0 (0) | 4 (20) | 0 (0) | 3 (4.8) | |
| rsKIR(donor C2C2 to host C1Cx) | 0 (0) | 0 (0) | 6 (40) | 4 (6.5) | |
| KIR3DL1 single+group, n (%) | <.01 | ||||
| nsKIR(donor Bw6Bw6 to host Bw6Bw6) | 0 (0) | 0 (0) | 0 (0) | 25 (40.3) | |
| d-rsKIR(donor Bw4Bwx to host Bw4Bwx) | 17 (100) | 15 (75) | 11 (73.3) | 12 (19.4) | |
| dsKIR(donor Bw4Bwx to host Bw6Bw6) | 0 (0) | 5 (25) | 0 (0) | 13 (21) | |
| rsKIR(donor Bw6Bw6 to host Bw4Bwx) | 0 (0) | 0 (0) | 4 (26.7) | 12 (19.4) | |
| Acute GVHD, n (%) | NS | ||||
| I | 6 (35.3) | 4 (20) | 4 (26.7) | 17 (27.4) | |
| II | 2 (11.8) | 2 (10) | 3 (20) | 12 (19.4) | |
| III | 0 (0) | 1 (5) | 2 (13.3) | 5 (8.1) | |
| IV | 1 (5.9) | 1 (5.0) | 0 (0) | 3 (4.8) | |
| Relapse | 2 (11.8) | 1 (5.0) | 2 (13.3) | 4 (6.5) | |
| Disease-free survival | 13 (76.5) | 16 (80) | 11 (73.3) | 51 (82.3) | |
| OS | 14 (82.4) | 16 (80) | 11 (73.3) | 53 (85.5) |
| . | d-rsKIR . | dsKIR . | rsKIR . | nsKIR . | P . |
|---|---|---|---|---|---|
| n | 17 | 20 | 15 | 62 | |
| Sex of host, male, n (%) | 8 (47.1) | 11 (55) | 10 (66.7) | 40 (64.5) | NS |
| Age of host, median (range), y | 29 (18-53) | 42.5 (26-63) | 28 (15-43) | 31.5 (15-58) | .003 |
| Age of donor, median (range), y | 45 (14-64) | 27 (8-65) | 40 (13-54) | 29 (12-60) | NS |
| Donor and host sex group, n (%) | |||||
| Male-male | 8 (47.1) | 8 (40) | 10 (66.7) | 28 (45.2) | |
| Male-female | 8 (47.1) | 4 (20) | 3 (20) | 15 (24.2) | |
| Female-male | 0 (0) | 5 (25) | 0 (0) | 12 (19.4) | |
| Female-female | 1 (5.9) | 3 (15) | 2 (13.3) | 7 (11.3) | |
| Donor and host relationship, n (%) | |||||
| Child-parent | 4 (23.5) | 12 (60) | 3 (20) | 22 (35.5) | |
| Sibling | 3 (17.6) | 3 (15) | 5 (33.3) | 22 (35.5) | |
| Parent-child | 10 (58.8) | 5 (25) | 7 (46.7) | 18 (29) | |
| Disease category, n (%) | <.01 | ||||
| AML | 10 (58.8) | 7 (35) | 4 (26.7) | 37 (50.9) | |
| ALL | 2 (11.8) | 3 (15) | 8 (53.3) | 21 (33.9) | |
| CML | 2 (11.8) | 0 (0) | 1 (6.7) | 2 (3.2) | |
| MDS | 3 (17.6) | 10 (50) | 2 (13.3) | 2 (3.2) | |
| Disease risk, n (%) | |||||
| High | 6 (35.3) | 10 (50) | 4 (26.7) | 9 (14.5) | .011 |
| HCT-CI score, n (%) | NS | ||||
| 0 | 15 (88.2) | 18 (90) | 11 (73.3) | 56 (90.3) | |
| ≥1 | 2 (11.8) | 2 (10) | 4 (26.7) | 6 (9.7) | |
| MRD status before transplantation, n (%) | NS | ||||
| Negative | 10 (58.8) | 8 (40) | 6 (40) | 29 (46.8) | |
| FCM and molecular positive | 5 (29.4) | 8 (40) | 4 (26.7) | 11 (17.7) | |
| Only FCM positive | 1 (5.9) | 3 (15) | 2 (13.3) | 6 (9.7) | |
| Only molecular positive | 1 (5.9) | 1 (5.0) | 3 (20) | 16 (25.8) | |
| Loci of HLA-A,B,DR mismatch, n (%) | NS | ||||
| 1 | 1 (5.9) | 0 (0) | 0 (0) | 3 (4.8) | |
| 2 | 4 (23.5) | 1 (5.0) | 0 (0) | 10 (16.1) | |
| 3 | 12 (70.6) | 19 (95) | 15 (100) | 49 (79) | |
| Missing self (donor ligand view), n (%) | 0 (0) | 0 (0) | 15 (100) | 62 (100) | <.01 |
| Missing self (host ligand view), n (%) | 0 (0) | 20 (100) | 0 (0) | 62 (100) | <.01 |
| Ligand-ligand GVH mismatch, n (%) | 0 (0) | 20 (100) | 0 (0) | 11 (28.2) | <.01 |
| Donor KIR haplotype, n (%) | NS | ||||
| AA | 9 (52.9) | 9 (45) | 12 (80) | 33 (55) | |
| BX | 8 (47.1) | 11 (55) | 3 (20) | 27 (45) | |
| KIR2DL1 single+group, n (%) | <.01 | ||||
| nsKIR(donor C1C1 to host C1C1) | 0 (0) | 0 (0) | 0 (0) | 43 (69.4) | |
| d-rsKIR(donor C2Cx to host C2Cx) | 17 (100) | 6 (30) | 7 (46.7) | 9 (14.5) | |
| dsKIR(donor C2CX to host C1C1) | 0 (0) | 14 (70) | 0 (0) | 9 (14.5) | |
| rsKIR(donor C1C1 to host C2Cx) | 0 (0) | 0 (0) | 8 (53.3) | 1 (1.6) | |
| KIR2DL2/L3 single+group, n (%) | <.01 | ||||
| nsKIR (donor C2C2 to host C2C2) | 0 (0) | 0 (0) | 0 (0) | 1 (1.6) | |
| d-rsKIR (donor C1Cx to host C1Cx) | 17 (100) | 16 (80) | 9 (60) | 54 (88.5) | |
| dsKIR(donor C1CX to host C2C2) | 0 (0) | 4 (20) | 0 (0) | 3 (4.8) | |
| rsKIR(donor C2C2 to host C1Cx) | 0 (0) | 0 (0) | 6 (40) | 4 (6.5) | |
| KIR3DL1 single+group, n (%) | <.01 | ||||
| nsKIR(donor Bw6Bw6 to host Bw6Bw6) | 0 (0) | 0 (0) | 0 (0) | 25 (40.3) | |
| d-rsKIR(donor Bw4Bwx to host Bw4Bwx) | 17 (100) | 15 (75) | 11 (73.3) | 12 (19.4) | |
| dsKIR(donor Bw4Bwx to host Bw6Bw6) | 0 (0) | 5 (25) | 0 (0) | 13 (21) | |
| rsKIR(donor Bw6Bw6 to host Bw4Bwx) | 0 (0) | 0 (0) | 4 (26.7) | 12 (19.4) | |
| Acute GVHD, n (%) | NS | ||||
| I | 6 (35.3) | 4 (20) | 4 (26.7) | 17 (27.4) | |
| II | 2 (11.8) | 2 (10) | 3 (20) | 12 (19.4) | |
| III | 0 (0) | 1 (5) | 2 (13.3) | 5 (8.1) | |
| IV | 1 (5.9) | 1 (5.0) | 0 (0) | 3 (4.8) | |
| Relapse | 2 (11.8) | 1 (5.0) | 2 (13.3) | 4 (6.5) | |
| Disease-free survival | 13 (76.5) | 16 (80) | 11 (73.3) | 51 (82.3) | |
| OS | 14 (82.4) | 16 (80) | 11 (73.3) | 53 (85.5) |
High-risk patients were those with AML not CR1, MDS not RARS, or RCMD.
ALL, acute lymphoid leukemia; BW4, HLA-BW4; C1, HLA-C group 1; C2, HLA-C group 2; CML chronic myeloid leukemia; FCM, flow cytometry; MDS, myelodysplastic syndrome; NS, not significant.